Manila Times Business
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
LIKMEZ® (ATI-1501) commercial momentum building in U.S. market US$40 million NIAID award supporting VXV-01 advancement through Phase 1 HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the "Company” or "Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2026 ("FYE 2026”), and provid
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Upper Deck Announces Exclusive Autograph Trading Card Deal with 2026 NHL First Overall Pick Gavin Mckenna
1h ago
US strikes Iran sites after cargo ship attack
1h ago
Eagle Vision Security Announces Texas Expansion to Support Growing Demand for Intelligent Security Solutions
1h ago
City Style Hair Design Barbers Announces Relocation from Pitt Street to Kent Street After 20 Years in Sydney CBD
1h ago